Stock Ratings / Health Care / TRAW / options

APUS (37) AZTR (33) XBIO (32) CANF (25) ⌘ Pro Terminal →

Traws Pharma Inc. (TRAW) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is TRAW trading relative to its 50-day, 200-day, and 52-week technical levels?

TRAW last traded at $0.30 (-1.66% on volume of 199,527 shares), positioning the stock -37.50% below its 50-day simple moving average ($0.48) and -73.91% below its 200-day simple moving average ($1.15). Across its 52-week range of $0.29 to $3.23, TRAW sits at the 0.3% percentile with a 14-day RSI of 25.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.34).

Q: What is TRAW's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for TRAW.

$0.30 -1.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.30

Traws Pharma Inc. (TRAW) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $4.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TRAW Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TRAW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Traws Pharma Inc. (NASDAQ: TRAW) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.30 (-1.66% 1D, market cap $4.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TRAW ranks #783 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TRAW compare to APUS and AZTR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TRAW carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APUS (Apimeds Pharmaceuticals US Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -6.2%, cap $4.6M) and AZTR (Azitra Inc) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, TRAW leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TRAW?

▼

Per TRAW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001130598), Traws Pharma Inc. generated $2.8M in revenue (+1134.5% YoY), $9.2M in net income, and -$18.2M in free cash flow against $10.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.30 (-0.49%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRAW)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY TRAW SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 25.8 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.41-7.3% Next Q

Q2 (-2Q)

Grade E$0.38-2.6% Next Q

Q3 (-1Q)

Grade E$0.37-18.9% Next Q

Current

Grade E$0.30-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TRAW Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TRAW currently carries a cautious 31/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.48) and Max Pain ($0.32) forces dealer call-delta covering toward $3.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TRAW• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TRAW Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (TRAW)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for TRAW.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRAW)

✓Walkthrough of TRAW's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TRAW // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -80.13%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.30H $0.30L $0.30C $0.30VOL 199.5K

RES: $0.79SUP: $0.28SMA50: $0.48SMA200: $1.15

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TRAW Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TRAW Butterfly Map → + Track TRAW →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TRAW today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TRAW. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TRAW today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRAW)

Health Care Rank #783 of 1016 ⚔️ APUS vs TRAW Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TRAW vs. APUS, AZTR, XBIO, CANF)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Traws Pharma Inc. (TRAW) ranks #783 by composite RQD confidence (31/100, grade E) and #953 by equity capitalization ($4.5M). Within this direct 5-issuer industry benchmark cohort, TRAW leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. APUS currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with TRAW at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TRAW ACTIVE Traws Pharma Inc.	E	31/100	—	—	-35.0%	-1.66%	$4.5M	Benchmark Subject
APUS Apimeds Pharmaceuticals US Inc.	D-	37/100	—	—	-6.2%	-6.23%	$4.6M	/apus-vs-traw →
AZTR Azitra Inc	E	33/100	—	—	-35.0%	+1.60%	$4.7M	/aztr-vs-traw →
XBIO Xenetic Biosciences Inc.	E	32/100	—	—	-30.3%	-3.30%	$4.8M	/xbio-vs-traw →
CANF Can-Fite Biopharma Ltd each representing two (2)	E	25/100	—	—	-35.0%	-2.41%	$4.9M	/canf-vs-traw →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001130598

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Traws Pharma Inc. (TRAW) reported GAAP revenue of $2.8M (+1134.5% vs. FY2024 revenue of $226.0K , and +1134.5% cumulative change since FY2023) , GAAP net income of $9.2M, operating cash flow of -$18.2M, and free cash flow of -$18.2M (+39.0% YoY). On the balance sheet, TRAW closed FY2025 with $10.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.8M	$9.2M	-$18.2M	-$18.2M	$10.6M	—
FY2024 (FY)	2024-12-31	$226.0K	-$166.5M	-$29.8M	-$29.8M	$25.0M	—
FY2023 (FY)	2023-12-31	$226.0K	-$18.9M	-$17.9M	-$17.9M	—	—

3. TRAW Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TRAW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TRAW compare to APUS and AZTR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TRAW?

Where is TRAW trading relative to its 50-day, 200-day, and 52-week technical levels?

TRAW last traded at $0.30 (-1.66% on volume of 199,527 shares), positioning the stock -37.50% below its 50-day simple moving average ($0.48) and -73.91% below its 200-day simple moving average ($1.15). Across its 52-week range of $0.29 to $3.23, TRAW sits at the 0.3% percentile with a 14-day RSI of 25.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.34).

TRAW Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is TRAW's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for TRAW.

Direct Sub-Reports: TRAW RQD Cockpit TRAW 12M Forecast TRAW Earnings & Move TRAW Dividends & DRIP TRAW Insiders & 13F TRAW Whale Options TRAW Profit Sankey TRAW News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TRAW — Traws Pharma Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:53:29Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, TRAW scores 32 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 4 of 20, reflecting ROIC of -35% and an FCF yield of 0%; for a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow to support valuation. The Whale 13F Flow pillar scores 5 of 20 for institutional accumulation and options positioning, indicating weak institutional support in the source data. The Insider Conviction pillar scores 5 of 20 based on SEC Form 4 and Congressional PTR cluster flow, signaling limited insider confidence signals. The Macro Regime Fit pillar scores 8 of 20, with a beta of 1.0 and sector sensitivity, meaning the stock's market sensitivity offers no defensive cushion. The Forensic Balance Sheet pillar scores 10 of 20 with an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5, which together describe a weak but not distressed financial position. The upside case rests on the speculative possibility that the announced financing and any future operating improvement change these metrics; the valuation tradeoff is that the current price of $0.3 sits against a market capitalization of $4.6M and a 52-week range of $0.29 - $3.23, so the stock has already fallen sharply. The rating's combined reading is that forensic and cash-generation risk dominate the profile.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the lead headline reports Traws Pharma Establishes $50 Million Equity Financing Facility, and a related item states the company expects to receive $50 million in funding from Roth Principal Investments, LLC. Both items are flagged YELLOW in the feed. A Form 8-K filing dated 23 October is also referenced. The remaining items are general market listings or unrelated company coverage (Connect Biopharma, Nxera Pharma). Risk watch items include the dilutive implications of an equity facility at a $4.6M market capitalization, though the source data does not quantify dilution. The Butterfly supply-chain graph reports no proprietary signals.

Open Questions

What are the terms, dilution levels, and conditions of the $50 million equity financing facility relative to the $4.6M market capitalization?
Why does net margin show 68% while operating margin is -60% and FY 2025 net income is $9.2M against operating income of $-17.9M?
What are the reported cash and debt balances, which the financials list as N/A?
What are TRAW's products, clinical or commercial milestones, and revenue drivers?
What is the source of the 2.5 Altman Z-Score and 3/9 Piotroski F-Score, and what components drive them?

TRAW Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Traws Pharma Inc. (TRAW) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TRAW Debate Forum (3) ↓

🟡 MARKET WIRE The Globe and Mail • 18h ago

Traws Pharma Establishes $50 Million Equity Financing Facility

The Globe and Mail report covering Traws Pharma Inc. (TRAW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 21h ago

Traws Pharma, Inc. announced that it expects to receive $50 million in funding from Roth Principal Investments, LLC

www.marketscreener.com report covering Traws Pharma Inc. (TRAW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com South Africa • 1d ago

Form 8K Traws Pharma Inc For: 23 October By Investing.com

Investing.com South Africa report covering Traws Pharma Inc. (TRAW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher

Yahoo Finance report covering Traws Pharma Inc. (TRAW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Complete U.S. Stocks List: Prices, Performance and Key Data

TradingKey report covering Traws Pharma Inc. (TRAW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Nxera Pharma Co., Ltd. (4565.T) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Traws Pharma Inc. (TRAW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 1d ago

Form DEF 14A Traws Pharma Inc For: 20 October By Investing.com

Investing.com Canada report covering Traws Pharma Inc. (TRAW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com India • 1d ago

Form S-1 Traws Pharma Inc For: 26 October By Investing.com

Investing.com India report covering Traws Pharma Inc. (TRAW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TRAW Bull vs. Bear Conversation Board — What's Your Call at $0.30?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TRAW 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.26 (-13.3%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is TRAW (E • RQD 32/100) a Buy at $0.30?

Welcome to the TRAW (Traws Pharma Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.23 (-23.3%)

Spot @ $0.30

Pump the brakes on TRAW — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on TRAW, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Traws Pharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.35 (+16.7%)

Spot @ $0.30

TRAW cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on TRAW, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.30 (52-wk range $0.29 - $3.23), any beat on forward guidance forces shorts and underweight funds to chase.